Loading
BT
BioGene Therapeutics Inc. Stock: price and insider trades · Canada
BioGene Therapeutics Inc.: what insiders have been doing
Every trade that managers of BioGene Therapeutics Inc. disclose to SEDI is tracked on this page. In the past year (18 October 2025 to 18 October 2026), 2 filings came from 2 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Insider buying of BioGene Therapeutics Inc. has been absent for the past year.
Compared with its exchange (2,144 companies, median 12 filings), a count of 2 filings is below the norm.
Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
· cache
Last declaration on 19 July 2026
Declarations2 total
Common SharesTSXSEDI:4754102
Common SharesTSXSEDI:4733327
2 of 2 declarations
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. is a company focused on developing gene therapies to treat genetic diseases. It is listed on the XTSE.
